Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity

  • Fernandez-Rodríguez, Concepción|||0000-0002-5853-0843
  • Rodriguez-Sevilla, Juan Jose|||0000-0002-4741-7925
  • Fernández Ibarrondo, Lierni|||0000-0003-2612-0484
  • Sánchez González, Blanca
  • Gibert Fernandez, Joan|||0000-0002-0742-0759
  • Bento, Leyre|||0000-0001-9929-8617
  • Garcia, Juan Fernando|||0000-0001-6974-0806
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Díez-Feijoo, Ramón
  • Camacho, Laura
  • Garcia-Retortillo, M.|||0000-0001-6783-7604
  • Gimeno, Eva|||0000-0002-3534-6189
  • Colomo, Luis|||0000-0001-5236-5085
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13.2%), although all had undetectable HBV DNA. AntiHBcore (anti-HBc) cases presented with older age at diagnosis than anti-HBc cases (68.1 vs 57.2 years; P 5.007) and higher b2-microglobulin (56.3% vs 28.9%; P 5.04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV hepatitis during treatment and/or maintenance. Remarkably, anti-HBc patients had significantly lower 10-year progression-free survival (PFS; 12.9% vs 58.3%; P,.0001) and overall survival (OS; 22.0% vs 86.2%; P,.0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc cases had higher incidence of ARID1A mutations and absence of EP300 mutations, 2 key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile.